Cargando…

Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model

BACKGROUND: Despite a tremendous amount of information on the role of amyloid in Alzheimer’s disease (AD), almost all clinical trials testing this hypothesis have failed to generate clinically relevant cognitive effects. METHODS: We present an advanced mechanism-based and biophysically realistic qua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geerts, Hugo, Spiros, Athan, Roberts, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797372/ https://www.ncbi.nlm.nih.gov/pubmed/29394903 http://dx.doi.org/10.1186/s13195-018-0343-5

Ejemplares similares

Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach
por: Geerts, Hugo, et al.
Publicado: (2020)

Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology
por: Geerts, Hugo, et al.
Publicado: (2015)

A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson’s Disease
por: Roberts, Patrick, et al.
Publicado: (2016)

A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance
por: Spiros, Athan, et al.
Publicado: (2014)

F189. PERSONALIZED MEDICINE: ESTIMATING THE IMPACT OF GENOTYPES ON ANTIPSYCHOTIC EFFICACY USING A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH
por: Geerts, Hugo, et al.
Publicado: (2018)

Toward Predicting Impact of Common Genetic Variants on Schizophrenia Clinical Responses With Antipsychotics: A Quantitative System Pharmacology Study
por: Spiros, Athan, et al.
Publicado: (2021)

A biophysically realistic computer model of Alzheimer pathology to guide the development of symptomatic drugs
por: Roberts, Patrick D, et al.
Publicado: (2012)

Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action
por: Roberts, Patrick D, et al.
Publicado: (2012)

A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer’s disease
por: Geerts, Hugo, et al.
Publicado: (2013)

A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS research and development
por: Spiros, Athan, et al.
Publicado: (2012)

A Quantitative System Pharmacology Computer Model for Cognitive Deficits in Schizophrenia
por: Geerts, H, et al.
Publicado: (2013)

S221. QUANTITATIVE SYSTEMS PHARMACOLOGY AS AN ALTERNATIVE TO CHLORPROMAZINE EQUIVALENTS: PREDICTIVE VALIDATION FROM A CRIS DATABASE EXPERIMENT
por: Geerts, Hugo, et al.
Publicado: (2018)

Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse
por: Spiros, Athan, et al.
Publicado: (2010)

Blinded Prospective Evaluation of Computer-Based Mechanistic Schizophrenia Disease Model for Predicting Drug Response
por: Geerts, Hugo, et al.
Publicado: (2012)

A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease
por: Geerts, Hugo, et al.
Publicado: (2023)

Prediction of Efficacy of Vabicaserin, a 5-HT(2C) Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model
por: Liu, J, et al.
Publicado: (2014)

Cognitive Decline in Preclinical Alzheimer’s Disease: Amyloid-Beta versus Tauopathy
por: Huber, Colin M., et al.
Publicado: (2017)

Amyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance
por: Marr, Robert A., et al.
Publicado: (2014)

Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid
por: Lin, Lin, et al.
Publicado: (2022)

Amyloid Beta in Aging and Alzheimer’s Disease
por: Sehar, Ujala, et al.
Publicado: (2022)

Quantitative in vivo assessment of amyloid-beta phagocytic capacity in an Alzheimer’s disease mouse model
por: Lau, Shun-Fat, et al.
Publicado: (2021)

Amyloid-beta Alzheimer targets — protein processing, lipid rafts, and amyloid-beta pores
por: Arbor, Sage C., et al.
Publicado: (2016)

Integrating Experimentation and Quantitative Modeling to Enhance Discovery of Beta Amyloid Lowering Therapeutics for Alzheimer’s Disease
por: Lu, Yasong
Publicado: (2012)

Editorial on, “Amyloid-beta clearance in Alzheimer's disease”
por: Marr, Robert A.
Publicado: (2014)

Amyloid Beta and MicroRNAs in Alzheimer’s Disease
por: Amakiri, Nnana, et al.
Publicado: (2019)

Amyloid-beta immunotherapy: the hope for Alzheimer disease?
por: Barrera-Ocampo, Alvaro, et al.
Publicado: (2016)

Results of Beta Secretase-Inhibitor Clinical Trials Support Amyloid Precursor Protein-Independent Generation of Beta Amyloid in Sporadic Alzheimer’s Disease
por: Volloch, Vladimir, et al.
Publicado: (2018)

Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcare
por: Kadra, Giouliana, et al.
Publicado: (2018)

Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates
por: Ramakrishnan, Vidya, et al.
Publicado: (2022)

Amyloid Beta-Mediated Hypomethylation of Heme Oxygenase 1 Correlates with Cognitive Impairment in Alzheimer’s Disease
por: Sung, Hye Youn, et al.
Publicado: (2016)

Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer's disease
por: Roostaei, T, et al.
Publicado: (2017)

Non-linear Character of Plasma Amyloid Beta Over the Course of Cognitive Decline in Alzheimer’s Continuum
por: Pan, Feng-Feng, et al.
Publicado: (2022)

Pathological changes induced by Alzheimer’s brain inoculation in amyloid-beta plaque-bearing mice
por: Lam, Suzanne, et al.
Publicado: (2022)

The amyloid beta ion channel hypothesis of Alzheimer’s disease
por: Shirwany, Najeeb A, et al.
Publicado: (2007)

Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
por: Cheignon, C., et al.
Publicado: (2017)

Impaired hepatic amyloid-beta degradation in Alzheimer’s disease
por: Maarouf, Chera L., et al.
Publicado: (2018)

Diversity of Amyloid-beta Proteoforms in the Alzheimer’s Disease Brain
por: Wildburger, Norelle C., et al.
Publicado: (2017)

Amyloid-Beta: A Crucial Factor in Alzheimer's Disease
por: Sadigh-Eteghad, Saeed, et al.
Publicado: (2015)

The Beta Amyloid Dysfunction (BAD) Hypothesis for Alzheimer’s Disease
por: Hillen, Heinz
Publicado: (2019)

Natural Products Targeting Amyloid Beta in Alzheimer’s Disease
por: Lee, Joo-Hee, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o9raipu91b62p8dlmditg93p9i